{"gene":"FUNDC2","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":2022,"finding":"FUNDC2 interacts with SLC25A11 (the mitochondrial glutathione transporter) at the mitochondrial outer membrane to regulate mitochondrial GSH (mitoGSH) levels; FUNDC2 also affects the stability of both SLC25A11 and GPX4. Loss of FUNDC2 reduces mitoGSH and protects against ferroptosis (and DOX-induced cardiomyopathy) in mice.","method":"Co-immunoprecipitation, FUNDC2 knockout mouse model, ferroptosis assays (GSH/LPO measurement), SLC25A11 knockdown in KO cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal interaction identified, KO mouse model with cardiac phenotype, multiple orthogonal methods (Co-IP, genetic rescue, biochemical assays), published in peer-reviewed journal","pmids":["36037337"],"is_preprint":false},{"year":2022,"finding":"FUNDC2 inhibits mitofusin 1 (MFN1)-mediated outer mitochondrial membrane fusion by directly binding to the GTPase domain of MFN1 via its amino-terminal region, promoting mitochondrial fragmentation and reprogrammed cellular metabolism in liver cancer cells.","method":"Co-immunoprecipitation/pulldown with domain-mapping, FUNDC2 knockdown/overexpression, mitochondrial morphology imaging, metabolic profiling, mouse liver tumor model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain-mapping pulldown identifying specific interaction interface, KD in cancer cells with defined morphology/metabolic phenotype, in vivo tumor model, published peer-reviewed","pmids":["35710796"],"is_preprint":false},{"year":2018,"finding":"FUNDC2 binds the lipid PIP3 via its conserved N-terminal motif at the mitochondrial outer membrane, enabling AKT phosphorylation and downstream BAD phosphorylation in a PI3K/PIP3-dependent manner to maintain BCL-xL levels and platelet survival; FUNDC2 KO mice exhibit thrombocytopenia under hypoxia.","method":"Lipid-binding assay (PIP3 binding), FUNDC2 knockout mouse model, phosphorylation assays (AKT/BAD), platelet survival/apoptosis assays under hypoxia","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct lipid-binding demonstrated, KO mouse with quantified platelet phenotype, multiple downstream phosphorylation readouts in a peer-reviewed study","pmids":["29786068"],"is_preprint":false},{"year":2019,"finding":"FUNDC2 positively regulates platelet activation and aggregation through a PI3K-dependent AKT/GSK-3β/cGMP signaling axis; FUNDC2-knockout mice show impaired hemostasis and thrombosis in vivo.","method":"Platelet aggregation assays with multiple agonists (ADP, collagen, thrombin, ristocetin/VWF), FUNDC2 KO mouse tail bleeding and thrombosis models, AKT/GSK-3β phosphorylation assays, cGMP measurement","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse with in vivo hemostasis/thrombosis phenotype, multiple agonists and downstream pathway validated, replicates and extends prior mechanistic findings","pmids":["30576423"],"is_preprint":false},{"year":2021,"finding":"FUNDC2 in platelet-derived mitochondria induces mitochondrial translocation of PIP3 via its N-terminal domain, activating Akt/FOXO3a signaling and suppressing pro-apoptotic Bim accumulation at mitochondria in recipient neuronal cells after hypoxia/reoxygenation.","method":"Platelet mitochondria transplantation into SH-SY5Y cells, FUNDC2 expression analysis, PIP3 mitochondrial localization assay, Akt/FOXO3a/Bim pathway protein measurement","journal":"Cell transplantation","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single lab, mechanistic pathway validated by multiple markers but no direct mutagenesis or reciprocal Co-IP; extends prior FUNDC2/PIP3/AKT findings in a new cellular context","pmids":["34105393"],"is_preprint":false},{"year":2015,"finding":"FUNDC2/HCBP6 negatively regulates intracellular triglyceride levels in hepatocytes by suppressing SREBP1c-mediated FASN expression; miR-122 post-transcriptionally represses HCBP6 via its 3'-UTR.","method":"Knockdown/overexpression of HCBP6 with TG measurement, SREBP1c/FASN expression analysis, miR-122 overexpression with luciferase 3'-UTR reporter assay","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single lab, bidirectional manipulation with consistent TG readout, luciferase reporter for miR-122 regulation, but no reconstitution or structural validation","pmids":["25855506"],"is_preprint":false},{"year":2018,"finding":"FUNDC2/HCBP6 directly binds to the C/EBPβ-binding site in the SREBP1c promoter (−139 to +359 bp region) to upregulate SREBP1c transcription, thereby increasing intracellular TG levels.","method":"Chromatin immunoprecipitation (ChIP), promoter-reporter assays, EMSA or equivalent DNA-binding assay in vitro and in vivo","journal":"BMB reports","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct DNA binding at a defined promoter region demonstrated in vitro and in vivo, but single lab and limited methodological detail in abstract","pmids":["29187281"],"is_preprint":false},{"year":2020,"finding":"FUNDC2/HCBP6 regulates lipolysis and fatty acid oxidation via AMPK activation in vivo; HCBP6-KO mice on a high-fat diet exhibit aggravated fatty liver, impaired glucose homeostasis, and inability to maintain body temperature under cold challenge.","method":"HCBP6 knockout mouse model on high-fat diet, glucose tolerance test, Western blot for AMPK pathway, histological staining","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — KO mouse with defined metabolic phenotypes, AMPK pathway implicated, but single lab and limited mechanistic depth in abstract","pmids":["32535386"],"is_preprint":false},{"year":2022,"finding":"FUNDC2/HCBP6 upregulates UCP1 expression and increases mitochondrial number in brown adipocytes; HCBP6-KO in mice reduces UCP1, PGC1α, Cidea, and OXPHOS gene expression in brown adipose tissue, impairing thermogenesis.","method":"HCBP6 knockout mouse model under HFD and cold challenge, UCP1/PGC1α/Cidea expression by qRT-PCR and Western blot, transcriptomic analysis of BAT","journal":"Journal of thermal biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — KO mouse with defined thermogenic phenotype, transcriptomics, but single lab and mechanism between FUNDC2 and UCP1 not directly resolved","pmids":["36195403"],"is_preprint":false},{"year":2023,"finding":"FUNDC2 promotes triple-negative breast cancer cell proliferation, migration, and invasion via the AKT/GSK3β/GLI1 (Hedgehog) signaling pathway; FUNDC2 silencing inhibits tumor growth in vivo.","method":"FUNDC2 siRNA knockdown in TNBC cells, proliferation/migration/invasion assays, subcutaneous xenograft mouse model, AKT/GSK3β/GLI1 pathway protein analysis","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — KD with in vivo xenograft and defined pathway readout, but single lab, no reconstitution or direct binding demonstration","pmids":["37700593"],"is_preprint":false},{"year":2026,"finding":"FUNDC2 knockdown in 3T3-L1 adipocytes reverses hypertension-associated changes in mitochondrial dynamics and ferroptosis markers, and alters adipokine secretion; conditioned medium from FUNDC2-KD adipocytes changes VSMC phenotypic switching and migration.","method":"FUNDC2 knockdown in 3T3-L1 adipocytes, Western blot for mitochondrial dynamics/ferroptosis proteins, adipokine measurement, VSMC phenotype/migration assays with conditioned medium, TEM","journal":"Clinical and experimental hypertension","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, indirect readouts (conditioned medium), no direct mechanistic interaction demonstrated","pmids":["41477710"],"is_preprint":false},{"year":2006,"finding":"The HCBP6 (FUNDC2) promoter contains functional transcriptional elements; two promoter constructs (−1066 bp and −240 bp upstream) drive reporter gene expression at 3.1× and 6.4× above baseline in HepG2 and NIH3T3 cells.","method":"Promoter-reporter (pCAT3) transfection assay in HepG2 and NIH3T3 cells, CAT ELISA","journal":"Zhonghua gan zang bing za zhi","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single promoter-reporter method, no mechanistic follow-up on transcription factor identity","pmids":["16494772"],"is_preprint":false}],"current_model":"FUNDC2 is a conserved mitochondrial outer membrane protein that (1) interacts with the mitochondrial glutathione transporter SLC25A11 to maintain mitochondrial GSH levels and suppress ferroptosis; (2) binds the GTPase domain of MFN1 to inhibit mitochondrial fusion, promoting fragmentation and metabolic reprogramming in cancer; (3) binds PIP3 via its N-terminal domain to sustain AKT/BAD/BCL-xL pro-survival signaling in platelets and AKT/GSK-3β/cGMP-dependent platelet activation; and (4) modulates lipid and glucose metabolism in hepatocytes via the SREBP1c/FASN transcriptional axis and AMPK activation."},"narrative":{"mechanistic_narrative":"FUNDC2 is a conserved mitochondrial outer membrane protein that integrates mitochondrial redox homeostasis, membrane dynamics, and lipid-dependent survival signaling across multiple cell types [PMID:36037337, PMID:35710796, PMID:29786068]. At the outer membrane it interacts with the mitochondrial glutathione transporter SLC25A11 and influences the stability of both SLC25A11 and GPX4, thereby sustaining mitochondrial glutathione pools; its loss lowers mitochondrial GSH and protects against ferroptosis and doxorubicin-induced cardiomyopathy [PMID:36037337]. FUNDC2 also restrains mitochondrial fusion by binding directly to the GTPase domain of MFN1 through its amino-terminal region, driving mitochondrial fragmentation and metabolic reprogramming in liver cancer cells [PMID:35710796]. Through a conserved N-terminal motif, FUNDC2 binds the lipid PIP3 at the outer membrane to support AKT phosphorylation, downstream BAD phosphorylation, and BCL-xL maintenance, a pathway required for platelet survival under hypoxia and, via an AKT/GSK-3β/cGMP axis, for platelet activation, aggregation, hemostasis, and thrombosis in vivo [PMID:29786068, PMID:30576423]. A parallel body of work on the same gene (HCBP6) places it in hepatic and adipose lipid and glucose metabolism, where it regulates SREBP1c/FASN-driven triglyceride handling and AMPK-dependent lipolysis and thermogenesis [PMID:25855506, PMID:32535386, PMID:36195403].","teleology":[{"year":2006,"claim":"Establishing that the HCBP6/FUNDC2 locus carries an active promoter provided the first evidence that the gene is transcriptionally regulated, setting the stage for later transcription-factor and metabolic studies.","evidence":"Promoter-reporter (pCAT3/CAT ELISA) assays in HepG2 and NIH3T3 cells","pmids":["16494772"],"confidence":"Low","gaps":["single promoter-reporter method with no follow-up on transcription factor identity","no link to protein function or localization","no in vivo validation"]},{"year":2015,"claim":"Linked FUNDC2/HCBP6 to hepatic lipid handling, answering whether the gene influences triglyceride metabolism and identifying miR-122 as an upstream post-transcriptional regulator.","evidence":"Knockdown/overexpression with TG measurement, SREBP1c/FASN expression, and miR-122 3'-UTR luciferase reporter in hepatocytes","pmids":["25855506"],"confidence":"Medium","gaps":["no reconstitution or structural validation","direction of SREBP1c regulation reported here as suppression, in tension with later promoter-binding work","mechanism connecting a mitochondrial protein to SREBP1c not resolved"]},{"year":2018,"claim":"Defined the molecular basis for FUNDC2-dependent platelet survival by showing direct PIP3 binding through its N-terminal motif drives AKT/BAD/BCL-xL signaling.","evidence":"PIP3 lipid-binding assay, FUNDC2 KO mice with hypoxic thrombocytopenia, AKT/BAD phosphorylation readouts","pmids":["29786068"],"confidence":"High","gaps":["structural basis of the PIP3-binding motif not solved","how a mitochondrial outer-membrane protein accesses PIP3 not fully explained"]},{"year":2018,"claim":"Provided a direct DNA-binding mechanism for HCBP6 in lipid metabolism, showing it binds the SREBP1c promoter to upregulate SREBP1c and raise triglycerides.","evidence":"ChIP, promoter-reporter, and DNA-binding assays at the C/EBPβ-binding site of the SREBP1c promoter","pmids":["29187281"],"confidence":"Medium","gaps":["single lab with limited methodological detail","opposite directionality versus the 2015 suppression finding unresolved","nuclear DNA-binding role hard to reconcile with mitochondrial localization"]},{"year":2019,"claim":"Extended the platelet PIP3/AKT mechanism to platelet activation, establishing FUNDC2 as a positive regulator of aggregation, hemostasis, and thrombosis through an AKT/GSK-3β/cGMP axis.","evidence":"Multi-agonist platelet aggregation assays, KO mouse tail-bleeding and thrombosis models, AKT/GSK-3β phosphorylation and cGMP measurement","pmids":["30576423"],"confidence":"High","gaps":["direct molecular link between FUNDC2 and cGMP generation not defined","no direct binding partners beyond the inferred PIP3/AKT module"]},{"year":2020,"claim":"Implicated HCBP6 in systemic lipid and glucose homeostasis via AMPK, showing KO mice develop aggravated fatty liver and impaired glucose handling and thermoregulation on high-fat diet.","evidence":"HCBP6 KO mice on HFD, glucose tolerance testing, AMPK pathway Western blots, histology","pmids":["32535386"],"confidence":"Medium","gaps":["mechanism connecting FUNDC2 to AMPK activation not defined","single lab, limited mechanistic depth"]},{"year":2021,"claim":"Tested whether FUNDC2's PIP3-dependent pro-survival function operates in trans, showing platelet-mitochondria transfer activates Akt/FOXO3a and suppresses Bim in recipient neurons after hypoxia/reoxygenation.","evidence":"Platelet mitochondria transplantation into SH-SY5Y cells, PIP3 mitochondrial localization, Akt/FOXO3a/Bim measurements","pmids":["34105393"],"confidence":"Medium","gaps":["no direct mutagenesis or reciprocal Co-IP","single lab","physiological relevance of inter-cellular mitochondrial transfer unestablished"]},{"year":2022,"claim":"Identified FUNDC2 as a regulator of mitochondrial glutathione and ferroptosis through interaction with SLC25A11, defining a redox-protective axis with cardiac relevance.","evidence":"Co-IP, FUNDC2 KO mouse model, GSH/lipid-peroxidation assays, SLC25A11 knockdown in KO cells","pmids":["36037337"],"confidence":"High","gaps":["structural basis of the FUNDC2–SLC25A11 interaction not solved","mechanism of GPX4/SLC25A11 stabilization not defined"]},{"year":2022,"claim":"Established FUNDC2 as a brake on mitochondrial fusion by mapping its N-terminal binding to the MFN1 GTPase domain, linking mitochondrial fragmentation to cancer metabolic reprogramming.","evidence":"Domain-mapping Co-IP/pulldown, knockdown/overexpression, mitochondrial morphology imaging, metabolic profiling, mouse liver tumor model","pmids":["35710796"],"confidence":"High","gaps":["structural details of the MFN1 GTPase interface not resolved","relationship between fusion control and the SLC25A11/ferroptosis role unexplored"]},{"year":2022,"claim":"Connected HCBP6 to thermogenic gene programs, showing KO reduces UCP1, PGC1α, Cidea, and OXPHOS expression and impairs thermogenesis in brown adipose tissue.","evidence":"HCBP6 KO mice under HFD/cold challenge, qRT-PCR/Western for thermogenic markers, BAT transcriptomics","pmids":["36195403"],"confidence":"Medium","gaps":["direct mechanism between FUNDC2 and UCP1 not resolved","single lab"]},{"year":2023,"claim":"Extended FUNDC2's pro-survival signaling to oncogenesis, showing it promotes triple-negative breast cancer growth through AKT/GSK3β/GLI1 (Hedgehog) signaling.","evidence":"FUNDC2 siRNA in TNBC cells, proliferation/migration/invasion assays, xenograft model, pathway protein analysis","pmids":["37700593"],"confidence":"Medium","gaps":["no direct binding or reconstitution","single lab","link to mitochondrial localization not addressed"]},{"year":2026,"claim":"Probed FUNDC2 in adipocyte-vascular crosstalk under hypertension, linking its knockdown to altered mitochondrial dynamics, ferroptosis markers, adipokine secretion, and VSMC phenotype switching.","evidence":"FUNDC2 knockdown in 3T3-L1 adipocytes, Western blots, adipokine measurement, conditioned-medium VSMC assays, TEM","pmids":["41477710"],"confidence":"Low","gaps":["indirect conditioned-medium readouts with no direct mechanistic interaction demonstrated","single lab","causal molecular link to vascular phenotype unestablished"]},{"year":null,"claim":"How FUNDC2's mitochondrial outer-membrane roles (SLC25A11/ferroptosis, MFN1/fusion, PIP3/AKT survival) mechanistically integrate with its reported nuclear/promoter and metabolic functions, and whether a single structural module underlies its multiple binding activities, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["no structural model of FUNDC2 or its binding interfaces","apparent contradiction between mitochondrial localization and direct SREBP1c promoter binding unreconciled","no unifying mechanism connecting redox, fusion, and lipid-signaling roles"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,4]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1]}],"localization":[],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,2]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,7]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[3]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3]}],"complexes":[],"partners":["SLC25A11","GPX4","MFN1","AKT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BWH2","full_name":"FUN14 domain-containing protein 2","aliases":["Cervical cancer proto-oncogene 3 protein","HCC-3","Hepatitis C virus core-binding protein 6"],"length_aa":189,"mass_kda":20.7,"function":"Binds directly and specifically 1,2-Diacyl-sn-glycero-3-phospho-(1'-myo-inositol-3',4',5'-bisphosphate) (PIP3) leading to the recruitment of PIP3 to mitochondria and may play a role in the regulation of the platelet activation via AKT/GSK3B/cGMP signaling pathways (PubMed:29786068). May act as transcription factor that regulates SREBP1 (isoform SREBP-1C) expression in order to modulate triglyceride (TG) homeostasis in hepatocytes (PubMed:25855506, PubMed:29187281)","subcellular_location":"Mitochondrion outer membrane; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9BWH2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FUNDC2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FUNDC2","total_profiled":1310},"omim":[{"mim_id":"301042","title":"FUN14 DOMAIN-CONTAINING PROTEIN 2; FUNDC2","url":"https://www.omim.org/entry/301042"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"tongue","ntpm":18.2}],"url":"https://www.proteinatlas.org/search/FUNDC2"},"hgnc":{"alias_symbol":["HCBP6","DC44"],"prev_symbol":[]},"alphafold":{"accession":"Q9BWH2","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BWH2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BWH2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BWH2-F1-predicted_aligned_error_v6.png","plddt_mean":65.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FUNDC2","jax_strain_url":"https://www.jax.org/strain/search?query=FUNDC2"},"sequence":{"accession":"Q9BWH2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BWH2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BWH2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BWH2"}},"corpus_meta":[{"pmid":"36037337","id":"PMC_36037337","title":"Mitochondrial outer membrane protein FUNDC2 promotes ferroptosis and contributes to doxorubicin-induced cardiomyopathy.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36037337","citation_count":130,"is_preprint":false},{"pmid":"35710796","id":"PMC_35710796","title":"FUNDC2 promotes liver tumorigenesis by inhibiting MFN1-mediated mitochondrial fusion.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35710796","citation_count":66,"is_preprint":false},{"pmid":"17683067","id":"PMC_17683067","title":"Double complex mutations involving F8 and FUNDC2 caused by distinct break-induced replication.","date":"2007","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/17683067","citation_count":50,"is_preprint":false},{"pmid":"29786068","id":"PMC_29786068","title":"Mitochondrial PIP3-binding protein FUNDC2 supports platelet survival via AKT signaling pathway.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29786068","citation_count":39,"is_preprint":false},{"pmid":"34105393","id":"PMC_34105393","title":"Platelet Mitochondria Transplantation Rescues Hypoxia/Reoxygenation-Induced Mitochondrial Dysfunction and Neuronal Cell Death Involving the FUNDC2/PIP3/Akt/FOXO3a Axis.","date":"2021","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/34105393","citation_count":31,"is_preprint":false},{"pmid":"30576423","id":"PMC_30576423","title":"FUNDC2 regulates platelet activation through AKT/GSK-3β/cGMP axis.","date":"2019","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/30576423","citation_count":17,"is_preprint":false},{"pmid":"25855506","id":"PMC_25855506","title":"HCBP6 Modulates Triglyceride Homeostasis in Hepatocytes Via the SREBP1c/FASN Pathway.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25855506","citation_count":16,"is_preprint":false},{"pmid":"32535386","id":"PMC_32535386","title":"HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32535386","citation_count":15,"is_preprint":false},{"pmid":"33193636","id":"PMC_33193636","title":"Deletion of FUNDC2 and CMC4 on Chromosome Xq28 Is Sufficient to Cause Hypergonadotropic Hypogonadism in Men.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33193636","citation_count":9,"is_preprint":false},{"pmid":"29735802","id":"PMC_29735802","title":"HCBP6 Is Involved in the Development of Hepatic Steatosis Induced by High-Fat Diet and CCL4 in Rats.","date":"2018","source":"Annals of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/29735802","citation_count":8,"is_preprint":false},{"pmid":"16494772","id":"PMC_16494772","title":"[Identification and evaluation promoter sequence and the transcription activation of Hcbp6 interaction with core protein of hepatitis C virus].","date":"2006","source":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/16494772","citation_count":5,"is_preprint":false},{"pmid":"37700593","id":"PMC_37700593","title":"FUNDC2, a mitochondrial outer membrane protein, mediates triple-negative breast cancer progression via the AKT/GSK3β/GLI1 pathway.","date":"2023","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/37700593","citation_count":4,"is_preprint":false},{"pmid":"29187281","id":"PMC_29187281","title":"HCBP6 upregulates human SREBP1c expression by binding to C/EBPβ-binding site in the SREBP1c promoter.","date":"2018","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/29187281","citation_count":4,"is_preprint":false},{"pmid":"40294153","id":"PMC_40294153","title":"Expression and immunological role of FUNDC2 in pan-cancer.","date":"2025","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/40294153","citation_count":0,"is_preprint":false},{"pmid":"36195403","id":"PMC_36195403","title":"HCBP6-induced activation of brown adipose tissue and upregulated of BAT cytokines genes.","date":"2022","source":"Journal of thermal biology","url":"https://pubmed.ncbi.nlm.nih.gov/36195403","citation_count":0,"is_preprint":false},{"pmid":"41477710","id":"PMC_41477710","title":"FUNDC2 contributes to hypertensive vascular remodeling by regulating mitochondrial dynamics and ferroptosis in perivascular adipose tissue.","date":"2026","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/41477710","citation_count":0,"is_preprint":false},{"pmid":"35468421","id":"PMC_35468421","title":"Methylation of the HCBP6 promoter is associated with primary biliary cholangitis pathogenesis.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35468421","citation_count":0,"is_preprint":false},{"pmid":"37005851","id":"PMC_37005851","title":"[Regulatory effect of eight Chinese herbal medicines on glucose and lipid metabolism and their potential active components based on HCBP6 target].","date":"2023","source":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica","url":"https://pubmed.ncbi.nlm.nih.gov/37005851","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10477,"output_tokens":3113,"usd":0.039063,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10647,"output_tokens":4238,"usd":0.079592,"stage2_stop_reason":"end_turn"},"total_usd":0.118655,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2022,\n      \"finding\": \"FUNDC2 interacts with SLC25A11 (the mitochondrial glutathione transporter) at the mitochondrial outer membrane to regulate mitochondrial GSH (mitoGSH) levels; FUNDC2 also affects the stability of both SLC25A11 and GPX4. Loss of FUNDC2 reduces mitoGSH and protects against ferroptosis (and DOX-induced cardiomyopathy) in mice.\",\n      \"method\": \"Co-immunoprecipitation, FUNDC2 knockout mouse model, ferroptosis assays (GSH/LPO measurement), SLC25A11 knockdown in KO cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal interaction identified, KO mouse model with cardiac phenotype, multiple orthogonal methods (Co-IP, genetic rescue, biochemical assays), published in peer-reviewed journal\",\n      \"pmids\": [\"36037337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FUNDC2 inhibits mitofusin 1 (MFN1)-mediated outer mitochondrial membrane fusion by directly binding to the GTPase domain of MFN1 via its amino-terminal region, promoting mitochondrial fragmentation and reprogrammed cellular metabolism in liver cancer cells.\",\n      \"method\": \"Co-immunoprecipitation/pulldown with domain-mapping, FUNDC2 knockdown/overexpression, mitochondrial morphology imaging, metabolic profiling, mouse liver tumor model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain-mapping pulldown identifying specific interaction interface, KD in cancer cells with defined morphology/metabolic phenotype, in vivo tumor model, published peer-reviewed\",\n      \"pmids\": [\"35710796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FUNDC2 binds the lipid PIP3 via its conserved N-terminal motif at the mitochondrial outer membrane, enabling AKT phosphorylation and downstream BAD phosphorylation in a PI3K/PIP3-dependent manner to maintain BCL-xL levels and platelet survival; FUNDC2 KO mice exhibit thrombocytopenia under hypoxia.\",\n      \"method\": \"Lipid-binding assay (PIP3 binding), FUNDC2 knockout mouse model, phosphorylation assays (AKT/BAD), platelet survival/apoptosis assays under hypoxia\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct lipid-binding demonstrated, KO mouse with quantified platelet phenotype, multiple downstream phosphorylation readouts in a peer-reviewed study\",\n      \"pmids\": [\"29786068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FUNDC2 positively regulates platelet activation and aggregation through a PI3K-dependent AKT/GSK-3β/cGMP signaling axis; FUNDC2-knockout mice show impaired hemostasis and thrombosis in vivo.\",\n      \"method\": \"Platelet aggregation assays with multiple agonists (ADP, collagen, thrombin, ristocetin/VWF), FUNDC2 KO mouse tail bleeding and thrombosis models, AKT/GSK-3β phosphorylation assays, cGMP measurement\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse with in vivo hemostasis/thrombosis phenotype, multiple agonists and downstream pathway validated, replicates and extends prior mechanistic findings\",\n      \"pmids\": [\"30576423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FUNDC2 in platelet-derived mitochondria induces mitochondrial translocation of PIP3 via its N-terminal domain, activating Akt/FOXO3a signaling and suppressing pro-apoptotic Bim accumulation at mitochondria in recipient neuronal cells after hypoxia/reoxygenation.\",\n      \"method\": \"Platelet mitochondria transplantation into SH-SY5Y cells, FUNDC2 expression analysis, PIP3 mitochondrial localization assay, Akt/FOXO3a/Bim pathway protein measurement\",\n      \"journal\": \"Cell transplantation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single lab, mechanistic pathway validated by multiple markers but no direct mutagenesis or reciprocal Co-IP; extends prior FUNDC2/PIP3/AKT findings in a new cellular context\",\n      \"pmids\": [\"34105393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FUNDC2/HCBP6 negatively regulates intracellular triglyceride levels in hepatocytes by suppressing SREBP1c-mediated FASN expression; miR-122 post-transcriptionally represses HCBP6 via its 3'-UTR.\",\n      \"method\": \"Knockdown/overexpression of HCBP6 with TG measurement, SREBP1c/FASN expression analysis, miR-122 overexpression with luciferase 3'-UTR reporter assay\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single lab, bidirectional manipulation with consistent TG readout, luciferase reporter for miR-122 regulation, but no reconstitution or structural validation\",\n      \"pmids\": [\"25855506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FUNDC2/HCBP6 directly binds to the C/EBPβ-binding site in the SREBP1c promoter (−139 to +359 bp region) to upregulate SREBP1c transcription, thereby increasing intracellular TG levels.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), promoter-reporter assays, EMSA or equivalent DNA-binding assay in vitro and in vivo\",\n      \"journal\": \"BMB reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct DNA binding at a defined promoter region demonstrated in vitro and in vivo, but single lab and limited methodological detail in abstract\",\n      \"pmids\": [\"29187281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FUNDC2/HCBP6 regulates lipolysis and fatty acid oxidation via AMPK activation in vivo; HCBP6-KO mice on a high-fat diet exhibit aggravated fatty liver, impaired glucose homeostasis, and inability to maintain body temperature under cold challenge.\",\n      \"method\": \"HCBP6 knockout mouse model on high-fat diet, glucose tolerance test, Western blot for AMPK pathway, histological staining\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — KO mouse with defined metabolic phenotypes, AMPK pathway implicated, but single lab and limited mechanistic depth in abstract\",\n      \"pmids\": [\"32535386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FUNDC2/HCBP6 upregulates UCP1 expression and increases mitochondrial number in brown adipocytes; HCBP6-KO in mice reduces UCP1, PGC1α, Cidea, and OXPHOS gene expression in brown adipose tissue, impairing thermogenesis.\",\n      \"method\": \"HCBP6 knockout mouse model under HFD and cold challenge, UCP1/PGC1α/Cidea expression by qRT-PCR and Western blot, transcriptomic analysis of BAT\",\n      \"journal\": \"Journal of thermal biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — KO mouse with defined thermogenic phenotype, transcriptomics, but single lab and mechanism between FUNDC2 and UCP1 not directly resolved\",\n      \"pmids\": [\"36195403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FUNDC2 promotes triple-negative breast cancer cell proliferation, migration, and invasion via the AKT/GSK3β/GLI1 (Hedgehog) signaling pathway; FUNDC2 silencing inhibits tumor growth in vivo.\",\n      \"method\": \"FUNDC2 siRNA knockdown in TNBC cells, proliferation/migration/invasion assays, subcutaneous xenograft mouse model, AKT/GSK3β/GLI1 pathway protein analysis\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — KD with in vivo xenograft and defined pathway readout, but single lab, no reconstitution or direct binding demonstration\",\n      \"pmids\": [\"37700593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"FUNDC2 knockdown in 3T3-L1 adipocytes reverses hypertension-associated changes in mitochondrial dynamics and ferroptosis markers, and alters adipokine secretion; conditioned medium from FUNDC2-KD adipocytes changes VSMC phenotypic switching and migration.\",\n      \"method\": \"FUNDC2 knockdown in 3T3-L1 adipocytes, Western blot for mitochondrial dynamics/ferroptosis proteins, adipokine measurement, VSMC phenotype/migration assays with conditioned medium, TEM\",\n      \"journal\": \"Clinical and experimental hypertension\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, indirect readouts (conditioned medium), no direct mechanistic interaction demonstrated\",\n      \"pmids\": [\"41477710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The HCBP6 (FUNDC2) promoter contains functional transcriptional elements; two promoter constructs (−1066 bp and −240 bp upstream) drive reporter gene expression at 3.1× and 6.4× above baseline in HepG2 and NIH3T3 cells.\",\n      \"method\": \"Promoter-reporter (pCAT3) transfection assay in HepG2 and NIH3T3 cells, CAT ELISA\",\n      \"journal\": \"Zhonghua gan zang bing za zhi\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single promoter-reporter method, no mechanistic follow-up on transcription factor identity\",\n      \"pmids\": [\"16494772\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FUNDC2 is a conserved mitochondrial outer membrane protein that (1) interacts with the mitochondrial glutathione transporter SLC25A11 to maintain mitochondrial GSH levels and suppress ferroptosis; (2) binds the GTPase domain of MFN1 to inhibit mitochondrial fusion, promoting fragmentation and metabolic reprogramming in cancer; (3) binds PIP3 via its N-terminal domain to sustain AKT/BAD/BCL-xL pro-survival signaling in platelets and AKT/GSK-3β/cGMP-dependent platelet activation; and (4) modulates lipid and glucose metabolism in hepatocytes via the SREBP1c/FASN transcriptional axis and AMPK activation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FUNDC2 is a conserved mitochondrial outer membrane protein that integrates mitochondrial redox homeostasis, membrane dynamics, and lipid-dependent survival signaling across multiple cell types [#0, #1, #2]. At the outer membrane it interacts with the mitochondrial glutathione transporter SLC25A11 and influences the stability of both SLC25A11 and GPX4, thereby sustaining mitochondrial glutathione pools; its loss lowers mitochondrial GSH and protects against ferroptosis and doxorubicin-induced cardiomyopathy [#0]. FUNDC2 also restrains mitochondrial fusion by binding directly to the GTPase domain of MFN1 through its amino-terminal region, driving mitochondrial fragmentation and metabolic reprogramming in liver cancer cells [#1]. Through a conserved N-terminal motif, FUNDC2 binds the lipid PIP3 at the outer membrane to support AKT phosphorylation, downstream BAD phosphorylation, and BCL-xL maintenance, a pathway required for platelet survival under hypoxia and, via an AKT/GSK-3\\u03b2/cGMP axis, for platelet activation, aggregation, hemostasis, and thrombosis in vivo [#2, #3]. A parallel body of work on the same gene (HCBP6) places it in hepatic and adipose lipid and glucose metabolism, where it regulates SREBP1c/FASN-driven triglyceride handling and AMPK-dependent lipolysis and thermogenesis [#5, #7, #8].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing that the HCBP6/FUNDC2 locus carries an active promoter provided the first evidence that the gene is transcriptionally regulated, setting the stage for later transcription-factor and metabolic studies.\",\n      \"evidence\": \"Promoter-reporter (pCAT3/CAT ELISA) assays in HepG2 and NIH3T3 cells\",\n      \"pmids\": [\"16494772\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"single promoter-reporter method with no follow-up on transcription factor identity\",\n        \"no link to protein function or localization\",\n        \"no in vivo validation\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked FUNDC2/HCBP6 to hepatic lipid handling, answering whether the gene influences triglyceride metabolism and identifying miR-122 as an upstream post-transcriptional regulator.\",\n      \"evidence\": \"Knockdown/overexpression with TG measurement, SREBP1c/FASN expression, and miR-122 3'-UTR luciferase reporter in hepatocytes\",\n      \"pmids\": [\"25855506\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"no reconstitution or structural validation\",\n        \"direction of SREBP1c regulation reported here as suppression, in tension with later promoter-binding work\",\n        \"mechanism connecting a mitochondrial protein to SREBP1c not resolved\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the molecular basis for FUNDC2-dependent platelet survival by showing direct PIP3 binding through its N-terminal motif drives AKT/BAD/BCL-xL signaling.\",\n      \"evidence\": \"PIP3 lipid-binding assay, FUNDC2 KO mice with hypoxic thrombocytopenia, AKT/BAD phosphorylation readouts\",\n      \"pmids\": [\"29786068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"structural basis of the PIP3-binding motif not solved\",\n        \"how a mitochondrial outer-membrane protein accesses PIP3 not fully explained\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided a direct DNA-binding mechanism for HCBP6 in lipid metabolism, showing it binds the SREBP1c promoter to upregulate SREBP1c and raise triglycerides.\",\n      \"evidence\": \"ChIP, promoter-reporter, and DNA-binding assays at the C/EBP\\u03b2-binding site of the SREBP1c promoter\",\n      \"pmids\": [\"29187281\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"single lab with limited methodological detail\",\n        \"opposite directionality versus the 2015 suppression finding unresolved\",\n        \"nuclear DNA-binding role hard to reconcile with mitochondrial localization\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended the platelet PIP3/AKT mechanism to platelet activation, establishing FUNDC2 as a positive regulator of aggregation, hemostasis, and thrombosis through an AKT/GSK-3\\u03b2/cGMP axis.\",\n      \"evidence\": \"Multi-agonist platelet aggregation assays, KO mouse tail-bleeding and thrombosis models, AKT/GSK-3\\u03b2 phosphorylation and cGMP measurement\",\n      \"pmids\": [\"30576423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"direct molecular link between FUNDC2 and cGMP generation not defined\",\n        \"no direct binding partners beyond the inferred PIP3/AKT module\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Implicated HCBP6 in systemic lipid and glucose homeostasis via AMPK, showing KO mice develop aggravated fatty liver and impaired glucose handling and thermoregulation on high-fat diet.\",\n      \"evidence\": \"HCBP6 KO mice on HFD, glucose tolerance testing, AMPK pathway Western blots, histology\",\n      \"pmids\": [\"32535386\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"mechanism connecting FUNDC2 to AMPK activation not defined\",\n        \"single lab, limited mechanistic depth\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Tested whether FUNDC2's PIP3-dependent pro-survival function operates in trans, showing platelet-mitochondria transfer activates Akt/FOXO3a and suppresses Bim in recipient neurons after hypoxia/reoxygenation.\",\n      \"evidence\": \"Platelet mitochondria transplantation into SH-SY5Y cells, PIP3 mitochondrial localization, Akt/FOXO3a/Bim measurements\",\n      \"pmids\": [\"34105393\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"no direct mutagenesis or reciprocal Co-IP\",\n        \"single lab\",\n        \"physiological relevance of inter-cellular mitochondrial transfer unestablished\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified FUNDC2 as a regulator of mitochondrial glutathione and ferroptosis through interaction with SLC25A11, defining a redox-protective axis with cardiac relevance.\",\n      \"evidence\": \"Co-IP, FUNDC2 KO mouse model, GSH/lipid-peroxidation assays, SLC25A11 knockdown in KO cells\",\n      \"pmids\": [\"36037337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"structural basis of the FUNDC2\\u2013SLC25A11 interaction not solved\",\n        \"mechanism of GPX4/SLC25A11 stabilization not defined\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established FUNDC2 as a brake on mitochondrial fusion by mapping its N-terminal binding to the MFN1 GTPase domain, linking mitochondrial fragmentation to cancer metabolic reprogramming.\",\n      \"evidence\": \"Domain-mapping Co-IP/pulldown, knockdown/overexpression, mitochondrial morphology imaging, metabolic profiling, mouse liver tumor model\",\n      \"pmids\": [\"35710796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"structural details of the MFN1 GTPase interface not resolved\",\n        \"relationship between fusion control and the SLC25A11/ferroptosis role unexplored\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected HCBP6 to thermogenic gene programs, showing KO reduces UCP1, PGC1\\u03b1, Cidea, and OXPHOS expression and impairs thermogenesis in brown adipose tissue.\",\n      \"evidence\": \"HCBP6 KO mice under HFD/cold challenge, qRT-PCR/Western for thermogenic markers, BAT transcriptomics\",\n      \"pmids\": [\"36195403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"direct mechanism between FUNDC2 and UCP1 not resolved\",\n        \"single lab\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended FUNDC2's pro-survival signaling to oncogenesis, showing it promotes triple-negative breast cancer growth through AKT/GSK3\\u03b2/GLI1 (Hedgehog) signaling.\",\n      \"evidence\": \"FUNDC2 siRNA in TNBC cells, proliferation/migration/invasion assays, xenograft model, pathway protein analysis\",\n      \"pmids\": [\"37700593\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"no direct binding or reconstitution\",\n        \"single lab\",\n        \"link to mitochondrial localization not addressed\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Probed FUNDC2 in adipocyte-vascular crosstalk under hypertension, linking its knockdown to altered mitochondrial dynamics, ferroptosis markers, adipokine secretion, and VSMC phenotype switching.\",\n      \"evidence\": \"FUNDC2 knockdown in 3T3-L1 adipocytes, Western blots, adipokine measurement, conditioned-medium VSMC assays, TEM\",\n      \"pmids\": [\"41477710\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"indirect conditioned-medium readouts with no direct mechanistic interaction demonstrated\",\n        \"single lab\",\n        \"causal molecular link to vascular phenotype unestablished\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FUNDC2's mitochondrial outer-membrane roles (SLC25A11/ferroptosis, MFN1/fusion, PIP3/AKT survival) mechanistically integrate with its reported nuclear/promoter and metabolic functions, and whether a single structural module underlies its multiple binding activities, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"no structural model of FUNDC2 or its binding interfaces\",\n        \"apparent contradiction between mitochondrial localization and direct SREBP1c promoter binding unreconciled\",\n        \"no unifying mechanism connecting redox, fusion, and lipid-signaling roles\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 4]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005741\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 7]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"SLC25A11\",\n      \"GPX4\",\n      \"MFN1\",\n      \"AKT1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}